Jentashapir Journal of Health Research

Published by: Kowsar

Curcumin as an Herbal Inhibitor Candidate Against HTLV-1 Protease

Mohsen Karbalaei 1 and Masoud Keikha ORCID 2 , *
Authors Information
1 Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran
2 Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Jentashapir Journal of Health Research: 10 (1); e92813
  • Published Online: July 13, 2019
  • Article Type: Letter
  • Received: May 2, 2019
  • Accepted: June 23, 2019
  • DOI: 10.5812/jjhr.92813

To Cite: Karbalaei M, Keikha M. Curcumin as an Herbal Inhibitor Candidate Against HTLV-1 Protease, Jentashapir J Health Res. Online ahead of Print ; 10(1):e92813. doi: 10.5812/jjhr.92813.

Copyright © 2019, Jentashapir Journal of Health Research. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
  • 1. Mirzaei H, Naseri G, Rezaee R, Mohammadi M, Banikazemi Z, Mirzaei HR, et al. Curcumin: A new candidate for melanoma therapy? Int J Cancer. 2016;139(8):1683-95. doi: 10.1002/ijc.30224. [PubMed: 27280688].
  • 2. Moghadamtousi SZ, Kadir HA, Hassandarvish P, Tajik H, Abubakar S, Zandi K. A review on antibacterial, antiviral, and antifungal activity of curcumin. Biomed Res Int. 2014;2014:186864. doi: 10.1155/2014/186864. [PubMed: 24877064]. [PubMed Central: PMC4022204].
  • 3. Chen TY, Chen DY, Wen HW, Ou JL, Chiou SS, Chen JM, et al. Inhibition of enveloped viruses infectivity by curcumin. PLoS One. 2013;8(5). e62482. doi: 10.1371/journal.pone.0062482. [PubMed: 23658730]. [PubMed Central: PMC3641039].
  • 4. Akram M, Tahir IM, Shah SMA, Mahmood Z, Altaf A, Ahmad K, et al. Antiviral potential of medicinal plants against HIV, HSV, influenza, hepatitis, and coxsackievirus: A systematic review. Phytother Res. 2018;32(5):811-22. doi: 10.1002/ptr.6024. [PubMed: 29356205].
  • 5. Martinez J, Coplan P, Wainberg MA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Res. 2006;71(2-3):343-50. doi: 10.1016/j.antiviral.2006.05.013. [PubMed: 16787667].
  • 6. Mohammadi A, Fazeli B, Taheri M, Sahebkar A, Poursina Z, Vakili V, et al. Modulatory effects of curcumin on apoptosis and cytotoxicity-related molecules in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients. Biomed Pharmacother. 2017;85:457-62. doi: 10.1016/j.biopha.2016.11.050. [PubMed: 27894665].
  • 7. Macchi B, Balestrieri E, Frezza C, Grelli S, Valletta E, Marcais A, et al. Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-alpha. Blood Adv. 2017;1(12):748-52. doi: 10.1182/bloodadvances.2016001370. [PubMed: 29296718]. [PubMed Central: PMC5728049 interests].
  • 8. Soltani A, Hashemy SI, Zahedi Avval F, Soleimani A, Rafatpanah H, Rezaee SA, et al. Molecular targeting for treatment of human T-lymphotropic virus type 1 infection. Biomed Pharmacother. 2019;109:770-8. doi: 10.1016/j.biopha.2018.10.139. [PubMed: 30551530].
  • 9. Einsiedel L, Purcell D, Schinke S, Haynes K, Taylor GP, Martin F. Highlights from the HTLV-1 symposium at the 2017 Australasian HIV and AIDS Conference held jointly with the 2017 Australasian Sexual Health Conference, November 2017, Canberra, Australia. J Virus Erad. 2018;4(1):48-50. [PubMed: 29568554]. [PubMed Central: PMC5851185].
  • 10. Kheirabadi M, Maleki J, Soufian S, Hosseini S. Design of new potent HTLV-1 protease inhibitors: In silico study. Mol Biol Res Commun. 2016;5(1):19-30. [PubMed: 27844017]. [PubMed Central: PMC5019330].
  • 11. Gross C, Thoma-Kress AK. Molecular mechanisms of HTLV-1 cell-to-cell transmission. Viruses. 2016;8(3):74. doi: 10.3390/v8030074. [PubMed: 27005656]. [PubMed Central: PMC4810264].
  • 12. Balestrieri E, Ascolani A, Igarashi Y, Oki T, Mastino A, Balzarini J, et al. Inhibition of cell-to-cell transmission of human T-cell lymphotropic virus type 1 in vitro by carbohydrate-binding agents. Antimicrob Agents Chemother. 2008;52(8):2771-9. doi: 10.1128/AAC.01671-07. [PubMed: 18505856]. [PubMed Central: PMC2493145].
  • 13. Li M, Laco GS, Jaskolski M, Rozycki J, Alexandratos J, Wlodawer A, et al. Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design. Proc Natl Acad Sci U S A. 2005;102(51):18332-7. doi: 10.1073/pnas.0509335102. [PubMed: 16352712]. [PubMed Central: PMC1317974].
  • 14. Selvaraj C, Singh P, Singh SK. Molecular insights on analogs of HIV PR inhibitors toward HTLV-1 PR through QM/MM interactions and molecular dynamics studies: Comparative structure analysis of wild and mutant HTLV-1 PR. J Mol Recognit. 2014;27(12):696-706. doi: 10.1002/jmr.2395. [PubMed: 25319617].
  • 15. Burger D, Boyd M, Duncombe C, Felderhof M, Mahanontharit A, Ruxrungtham K, et al. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients. J Antimicrob Chemother. 2003;51(5):1231-8. doi: 10.1093/jac/dkg198. [PubMed: 12668574].
  • 16. Cho JA, Park E. Curcumin utilizes the anti-inflammatory response pathway to protect the intestine against bacterial invasion. Nutr Res Pract. 2015;9(2):117-22. doi: 10.4162/nrp.2015.9.2.117. [PubMed: 25861416]. [PubMed Central: PMC4388941].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments